{"id":28638,"date":"2023-01-05T12:56:24","date_gmt":"2023-01-05T12:56:24","guid":{"rendered":"http:\/\/myanmarnewswire.com\/?guid=36bc1d5a845b3533f015e17041e59b2f"},"modified":"2023-01-05T12:56:24","modified_gmt":"2023-01-05T12:56:24","slug":"curative-biotechnology-announces-completion-of-ind-enabling-reformulated-metformin-hcl-eye-drop-study","status":"publish","type":"post","link":"https:\/\/myanmarnewswire.com\/curative-biotechnology-announces-completion-of-ind-enabling-reformulated-metformin-hcl-eye-drop-study\/","title":{"rendered":"Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study"},"content":{"rendered":"
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (\u201cCurative Biotech\u201d or the \u201cCompany\u201d), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits.<\/p>\n
Paul Michaels, Chairman and President of Curative Biotechnology, said, \u201cWe are pleased to announce the successful completion of these important studies, outlined in our Pre IND meeting with the FDA. We are now able to move on to preparing the Company\u2019s first IND application to move our Metformin reformulation into a clinical trial to treat Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographical Atrophy (GA) resulting from AMD.\u201d<\/p>\n
Michaels continued, \u201cBoth Dry AMD and GA are currently unmet medical needs with no FDA approved efficacious treatment options. As previously announced<\/a>, we will be conducting the first in human study under a CRADA (Cooperative Research and Development Agreement) with the National Eye Institute of the National Institutes of Health, in Bethesda Maryland.\u201d<\/p>\n About Macular Degeneration (AMD)<\/strong><\/p>\n Macular Degeneration<\/a> is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).<\/p>\n